U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
1. Johnson & Johnson's INLEXZO™ gains FDA approval for bladder cancer treatment. 2. 82% of patients with BCG-unresponsive NMIBC achieve complete response with INLEXZO™. 3. The treatment allows bladder preservation, reducing need for radical cystectomy. 4. INLEXZO™ is first-of-its-kind, offering hope to BCG-unresponsive patients. 5. Safety profile is established with manageable adverse effects.